Elephas is an in vivo tumor imaging diagnostic service provider whose platform leverages the latest research in cancer biology, multimodal microscopy and artificial intelligence to help enhance clinical decision-making and accelerate drug development. Elephas is helping cancer researchers accelerate the development of immunotherapy drugs by developing Cybrid™, an in vivo tumor imaging platform to assess the response of living tumor fragments to cancer therapy. Using live fragments from patient biopsies, the platform uses multiphoton imaging and multiple assays to assess patient response to therapy, particularly immunotherapy. Elephas Biosciences Corporation announced a $41.5 million Series B round led by ARCH Venture Partners, with participation from Moore Strategic Ventures, Tao Capital Partners, Northpond Ventures, Sands Capital and WARF Ventures.
This article is reproduced from: https://www.itjuzi.com/investevent/13531619
This site is for inclusion only, and the copyright belongs to the original author.